Mitsubishi Tanabe Ph (MTZXF) 17.5500 $MTZXF
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 229.02 (-9.60), UTHR: 102.11 (-3.17), CTIC: 0.37 (-0.03), CHRS: 15.32 (-1.15), JNJ: 115.63 (-1.75), NPSP: 45.97 (+0.01), IBIO: 0.63 (unch), EBS: 29.34 (-1.31), SLXP: 172.96 (+0.15), AMGN: 146.45 (-5.82), SPPI: 6.47 (-0.34), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), ANIK: 51.09 (-0.01), NVO: 51.06 (-2.34), BAX: 43.85 (-2.11), MRK: 55.88 (-1.80), NVS: 77.10 (-3.57)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
BusinessWire - Wed Oct 21, 6:30AM CDT
--First patient enrolled in aducanumab Phase 3 studies for Alzheimer's disease
BIIB: 229.02 (-9.60)
Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 24.13 (-2.26), IMMU: 2.17 (-0.33), AMGN: 146.45 (-5.82), GSK: 40.80 (-1.76), BMY: 70.61 (-2.03), JNJ: 115.63 (-1.75), ARGS: 5.51 (-0.09), ANTH: 3.17 (+0.07), ABBV: 59.86 (-1.45), CBMG: 13.09 (-1.15), KPTI: 7.52 (-0.51), CELGZ: 1.42 (-0.03)
Global Secondary Hyperparathyroidism Pipeline Review 2015 - 5 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bsvf9t/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Deltanoid Pharmaceuticals Inc. - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - OPKO Health, Inc. Drug Profiles - Calcifediol MR - Calcimimetic-18 - CTA-091 - CTAP-201 - DP-001 - Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Cancer - etelcalcetide - lunacalcipol - MT-4580 - NKTR-228 - VS-105 - VS-110 - VS-411 For more information visit http://www.researchandmarkets.com/research/bsvf9t/secondary
OPK: 9.46 (-0.29), AMGN: 146.45 (-5.82), NKTR: 14.38 (-1.16)
Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 81.90 (-6.30), ATHX: 1.97 (-0.03), ACOR: 25.24 (-1.07), LPTN: 2.18 (-0.18), OMER: 10.28 (-0.70), CUR: 0.26 (-0.03)
Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
PR Newswire - Thu Oct 01, 3:05PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration with Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) providing MTPC with exclusive development and commercial rights to fasinumab (REGN475), Regeneron's NGF antibody in late-stage development for musculoskeletal pain. Under the terms of the agreement, MTPC will obtain exclusive development and commercial rights to fasinumab in Japan, Korea and nine other Asian countries, excluding China.
REGN: 339.48 (-17.66)
Cardiome and Mitsubishi Tanabe Pharma Europe signs co-promotion agreement in the UK for AGGRASTAT and EXEMBOL
M2 - Thu Oct 01, 4:04AM CDT
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) revealed on Wednesday the launch of an agreement to co-promote AGGRASTAT (tirofiban HCL) and EXEMBOL (argatroban monohydrate) in the UK for an undisclosed value.
CRME: 4.88 (-0.12), COM.TO: 6.40 (+0.05)
Cardiome and Mitsubishi Tanabe Pharma Europe Enter Into an AGGRASTAT and EXEMBOL Co-Promotion Agreement in the UK
PR Newswire - Wed Sep 30, 7:00AM CDT
NASDAQ: CRME TSX: COM
CRME: 4.88 (-0.12), COM.TO: 6.40 (+0.05)
Biogen Licenses Mitsubishi Tanabe Pharma's Phase 2 Molecule for Autoimmune Diseases
BusinessWire - Wed Sep 09, 2:26AM CDT
--Mitsubishi Tanabe Pharma to receive $60 million Upfront with Potential Milestone Payments and Royalties
BIIB: 229.02 (-9.60)
Chronic Plaque Psoriasis Pipeline Review 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Sep 08, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/clbhgf/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Almirall, S.A. - Boehringer Ingelheim GmbH - Cellceutix Corporation - Coherus BioSciences, Inc. - Eli Lilly and Company - GlaxoSmithKline Plc - Johnson & Johnson - Mitsubishi Tanabe Pharma Corporation - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Takeda Pharmaceutical Company Limited - UCB S.A. - XenoPort, Inc. Drug Profiles - AbGn-168H - adalimumab biosimilar - adalimumab biosimilar - baricitinib - BI-655066 - C-82 - certolizumab pegol - CJM-112 - COVA-322 - dimethyl fumarate - etanercept biosimilar - etanercept biosimilar - etanercept biosimilar - GSK-2831781 - ixekizumab - KM-133 - lunacalcipol - MT-1303 - namilumab - orilotimod potassium - tildrakizumab - tofacitinib - XP-23829 For more information visit http://www.researchandmarkets.com/research/cl...nic_plaque
JNJ: 115.63 (-1.75), OPK: 9.46 (-0.29), PFE: 33.97 (-0.62), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), XNPT: 7.01 (-0.02), NVS: 77.10 (-3.57), CHRS: 15.32 (-1.15)
Global Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Sep 08, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/32f36p/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - Polyneuron Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - Cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - immune globulin (human) - LUNAR-102 - Monoclonal Antibody for CIDP - NNZ-2591 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - PN-1007 - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/32f36p/peripheral
INSY: 12.62 (-0.45), PFE: 33.97 (-0.62)
Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.45 (-0.03), APRI: 0.40 (-0.07), ACOR: 25.24 (-1.07)
Investigation Report on China's Pranoprofen Market, 2010-2019
PR Newswire Europe - Fri Aug 28, 1:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4hwkk/investigation [http://www.researchandmarkets.com/research/r4hwkk/investigation]) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" [http://www.researchandmarkets.com/research/r4hwkk/investigation] report to their offering.
Research and Markets: Investigation Report on China's Pranoprofen Market, 2010-2019
BusinessWire - Fri Aug 28, 10:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqfws4/investigation) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" report to their offering.
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 25.24 (-1.07), CVD: 106.42 (-0.71), JNJ: 115.63 (-1.75), ABBV: 59.86 (-1.45), ABT: 37.91 (-1.72), CBSTZ: 0.06 (unch), IMGN: 3.13 (-0.19), AMGN: 146.45 (-5.82), BMY: 70.61 (-2.03), GRFS: 15.50 (-0.58), GILD: 80.47 (-2.90), BAX: 43.85 (-2.11), AZN: 27.86 (-1.43), MRK: 55.88 (-1.80), NVS: 77.10 (-3.57), CELGZ: 1.42 (-0.03)
Systemic Lupus Erythematosus: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2p7pm/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects Companies Mentioned - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kymab Limited - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - National Pharmaceutical Corp. - Neovacs SA - Nippon Chemiphar Co., Ltd. - Padlock Therapeutics, Inc. - Pfizer Inc. - Plexxikon Inc. - RedHill Biopharma Ltd. - Redx Pharma Ltd - Resolve Therapeutics, LLC - Sanofi - Sarepta Therapeutics, Inc. - SATT Conectus Alsace SAS - SBI Biotech Co., Ltd. - Seattle Genetics, Inc. - Takeda Pharmaceutical Company Limited - Therapix Biosciences Ltd - UCB S.A. - Xencor, Inc. - XTL Biopharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/c2...emic_lupus
RDHL: 10.59 (-0.28), JNJ: 115.63 (-1.75), ANTH: 3.17 (+0.07), SRPT: 18.52 (+0.64), ABBV: 59.86 (-1.45), XNCR: 13.40 (-1.03), CBMG: 13.09 (-1.15), MGNX: 24.13 (-2.26), IMMU: 2.17 (-0.33), PFE: 33.97 (-0.62), AMGN: 146.45 (-5.82), BMY: 70.61 (-2.03), GSK: 40.80 (-1.76), ARGS: 5.51 (-0.09), SGEN: 37.59 (-2.48), CELGZ: 1.42 (-0.03)
Diabetes, Metabolic Syndrome and Cardiovascular Disease - 2015 Global Study
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qn9zj/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles - 30 of the 65 Companies - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca PLC - Bayer - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Debiotech - DexCom - Echo Therapeutics, Inc. - Eli Lilly - FIFTY50 Medical, Inc. - Flamel Technologies - Generex Biotechnology Corporation - Lexicon Pharmaceuticals - MannKind Corporation - Medipacs - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis For more information visit http://www.researchandmarkets.com/research/8qn9zj/diabetes
ABT: 37.91 (-1.72), MDT: 83.26 (-2.51), LXRX: 13.65 (-0.28), AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39), ECTE: 1.66 (-0.09), JNJ: 115.63 (-1.75), AZN: 27.86 (-1.43), MRK: 55.88 (-1.80), NVS: 77.10 (-3.57)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 229.02 (-9.60), UTHR: 102.11 (-3.17), CTIC: 0.37 (-0.03), CHRS: 15.32 (-1.15), JNJ: 115.63 (-1.75), NPSP: 45.97 (+0.01), IBIO: 0.63 (unch), EBS: 29.34 (-1.31), SLXP: 172.96 (+0.15), AMGN: 146.45 (-5.82), SPPI: 6.47 (-0.34), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), ANIK: 51.09 (-0.01), NVO: 51.06 (-2.34), BAX: 43.85 (-2.11), MRK: 55.88 (-1.80), NVS: 77.10 (-3.57)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
BusinessWire - Wed Oct 21, 6:30AM CDT
--First patient enrolled in aducanumab Phase 3 studies for Alzheimer's disease
BIIB: 229.02 (-9.60)
Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 24.13 (-2.26), IMMU: 2.17 (-0.33), AMGN: 146.45 (-5.82), GSK: 40.80 (-1.76), BMY: 70.61 (-2.03), JNJ: 115.63 (-1.75), ARGS: 5.51 (-0.09), ANTH: 3.17 (+0.07), ABBV: 59.86 (-1.45), CBMG: 13.09 (-1.15), KPTI: 7.52 (-0.51), CELGZ: 1.42 (-0.03)
Global Secondary Hyperparathyroidism Pipeline Review 2015 - 5 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bsvf9t/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Deltanoid Pharmaceuticals Inc. - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - OPKO Health, Inc. Drug Profiles - Calcifediol MR - Calcimimetic-18 - CTA-091 - CTAP-201 - DP-001 - Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Cancer - etelcalcetide - lunacalcipol - MT-4580 - NKTR-228 - VS-105 - VS-110 - VS-411 For more information visit http://www.researchandmarkets.com/research/bsvf9t/secondary
OPK: 9.46 (-0.29), AMGN: 146.45 (-5.82), NKTR: 14.38 (-1.16)
Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 81.90 (-6.30), ATHX: 1.97 (-0.03), ACOR: 25.24 (-1.07), LPTN: 2.18 (-0.18), OMER: 10.28 (-0.70), CUR: 0.26 (-0.03)
Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
PR Newswire - Thu Oct 01, 3:05PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration with Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) providing MTPC with exclusive development and commercial rights to fasinumab (REGN475), Regeneron's NGF antibody in late-stage development for musculoskeletal pain. Under the terms of the agreement, MTPC will obtain exclusive development and commercial rights to fasinumab in Japan, Korea and nine other Asian countries, excluding China.
REGN: 339.48 (-17.66)
Cardiome and Mitsubishi Tanabe Pharma Europe signs co-promotion agreement in the UK for AGGRASTAT and EXEMBOL
M2 - Thu Oct 01, 4:04AM CDT
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) revealed on Wednesday the launch of an agreement to co-promote AGGRASTAT (tirofiban HCL) and EXEMBOL (argatroban monohydrate) in the UK for an undisclosed value.
CRME: 4.88 (-0.12), COM.TO: 6.40 (+0.05)
Cardiome and Mitsubishi Tanabe Pharma Europe Enter Into an AGGRASTAT and EXEMBOL Co-Promotion Agreement in the UK
PR Newswire - Wed Sep 30, 7:00AM CDT
NASDAQ: CRME TSX: COM
CRME: 4.88 (-0.12), COM.TO: 6.40 (+0.05)
Biogen Licenses Mitsubishi Tanabe Pharma's Phase 2 Molecule for Autoimmune Diseases
BusinessWire - Wed Sep 09, 2:26AM CDT
--Mitsubishi Tanabe Pharma to receive $60 million Upfront with Potential Milestone Payments and Royalties
BIIB: 229.02 (-9.60)
Chronic Plaque Psoriasis Pipeline Review 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Sep 08, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/clbhgf/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Almirall, S.A. - Boehringer Ingelheim GmbH - Cellceutix Corporation - Coherus BioSciences, Inc. - Eli Lilly and Company - GlaxoSmithKline Plc - Johnson & Johnson - Mitsubishi Tanabe Pharma Corporation - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Takeda Pharmaceutical Company Limited - UCB S.A. - XenoPort, Inc. Drug Profiles - AbGn-168H - adalimumab biosimilar - adalimumab biosimilar - baricitinib - BI-655066 - C-82 - certolizumab pegol - CJM-112 - COVA-322 - dimethyl fumarate - etanercept biosimilar - etanercept biosimilar - etanercept biosimilar - GSK-2831781 - ixekizumab - KM-133 - lunacalcipol - MT-1303 - namilumab - orilotimod potassium - tildrakizumab - tofacitinib - XP-23829 For more information visit http://www.researchandmarkets.com/research/cl...nic_plaque
JNJ: 115.63 (-1.75), OPK: 9.46 (-0.29), PFE: 33.97 (-0.62), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), XNPT: 7.01 (-0.02), NVS: 77.10 (-3.57), CHRS: 15.32 (-1.15)
Global Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Sep 08, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/32f36p/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - Polyneuron Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - Cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - immune globulin (human) - LUNAR-102 - Monoclonal Antibody for CIDP - NNZ-2591 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - PN-1007 - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/32f36p/peripheral
INSY: 12.62 (-0.45), PFE: 33.97 (-0.62)
Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.45 (-0.03), APRI: 0.40 (-0.07), ACOR: 25.24 (-1.07)
Investigation Report on China's Pranoprofen Market, 2010-2019
PR Newswire Europe - Fri Aug 28, 1:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4hwkk/investigation [http://www.researchandmarkets.com/research/r4hwkk/investigation]) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" [http://www.researchandmarkets.com/research/r4hwkk/investigation] report to their offering.
Research and Markets: Investigation Report on China's Pranoprofen Market, 2010-2019
BusinessWire - Fri Aug 28, 10:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqfws4/investigation) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" report to their offering.
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 25.24 (-1.07), CVD: 106.42 (-0.71), JNJ: 115.63 (-1.75), ABBV: 59.86 (-1.45), ABT: 37.91 (-1.72), CBSTZ: 0.06 (unch), IMGN: 3.13 (-0.19), AMGN: 146.45 (-5.82), BMY: 70.61 (-2.03), GRFS: 15.50 (-0.58), GILD: 80.47 (-2.90), BAX: 43.85 (-2.11), AZN: 27.86 (-1.43), MRK: 55.88 (-1.80), NVS: 77.10 (-3.57), CELGZ: 1.42 (-0.03)
Systemic Lupus Erythematosus: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2p7pm/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects Companies Mentioned - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kymab Limited - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - National Pharmaceutical Corp. - Neovacs SA - Nippon Chemiphar Co., Ltd. - Padlock Therapeutics, Inc. - Pfizer Inc. - Plexxikon Inc. - RedHill Biopharma Ltd. - Redx Pharma Ltd - Resolve Therapeutics, LLC - Sanofi - Sarepta Therapeutics, Inc. - SATT Conectus Alsace SAS - SBI Biotech Co., Ltd. - Seattle Genetics, Inc. - Takeda Pharmaceutical Company Limited - Therapix Biosciences Ltd - UCB S.A. - Xencor, Inc. - XTL Biopharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/c2...emic_lupus
RDHL: 10.59 (-0.28), JNJ: 115.63 (-1.75), ANTH: 3.17 (+0.07), SRPT: 18.52 (+0.64), ABBV: 59.86 (-1.45), XNCR: 13.40 (-1.03), CBMG: 13.09 (-1.15), MGNX: 24.13 (-2.26), IMMU: 2.17 (-0.33), PFE: 33.97 (-0.62), AMGN: 146.45 (-5.82), BMY: 70.61 (-2.03), GSK: 40.80 (-1.76), ARGS: 5.51 (-0.09), SGEN: 37.59 (-2.48), CELGZ: 1.42 (-0.03)
Diabetes, Metabolic Syndrome and Cardiovascular Disease - 2015 Global Study
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qn9zj/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles - 30 of the 65 Companies - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca PLC - Bayer - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Debiotech - DexCom - Echo Therapeutics, Inc. - Eli Lilly - FIFTY50 Medical, Inc. - Flamel Technologies - Generex Biotechnology Corporation - Lexicon Pharmaceuticals - MannKind Corporation - Medipacs - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis For more information visit http://www.researchandmarkets.com/research/8qn9zj/diabetes
ABT: 37.91 (-1.72), MDT: 83.26 (-2.51), LXRX: 13.65 (-0.28), AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39), ECTE: 1.66 (-0.09), JNJ: 115.63 (-1.75), AZN: 27.86 (-1.43), MRK: 55.88 (-1.80), NVS: 77.10 (-3.57)
